B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
$ 6.50 · 4.9 (658) · In stock
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
Digital Diabetes Management Market Size, Trends & Forecast
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement
Digital Diabetes Management Market Size, Trends & Forecast
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
Hip Replacement Devices Market Size, Share, Trends, Scope & Forecast
Digital Diabetes Management Market Size, Trends & Forecast
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
新闻详情页-B. Braun Group
Apheresis Machines Market 2021: Comprehensive Study Explores
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum